JMJanne Marie Moll

Janne Marie Moll

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Janne Marie Moll has a total of 249 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Author Correction: Early-life colonization by aromatic-lactate-producing bifidobacteria lowers the risk of allergic sensitization

    by Pernille Neve Myers, Rasmus Kaae Dehli, Axel Mie, Janne Marie Moll, Henrik Munch Roager, Carsten Eriksen, Martin Frederik Laursen, Ellen Magdalena Staudinger, Ioanna Chatzigiannidou, Pi Lærke Johansen, et al.

  • Open Access

    Multi-omic Characterization of the Oral Ecosystem and Assessment of Dental Health and Dental Hygiene Metadata in the Participants from a Large Randomized Double-Blinded Clinical Study

    by Hannah Moglowsky, Sofronia M. Ringold, Rodney Jones, Natalie Wall, Alexander Gudjonsson, Thorsten Gravert, Janne Marie Moll, Anne O’DOnnell, Katie Lee, Emily A. Stein

    Increasing evidence highlights the important role the oral ecosystem plays in systemic health. Despite the fact that oral diseases affect nearly 3.5 billion people globally, our understanding of the precise drivers of these diseases remains limited. To bridge this gap and provide broader understanding of oral public health, a clinical study involving 595 participants 20-78 years of age was conducted over 8 weeks. Characterization of the oral ecosystem using metabolomics, metagenomics, and targeted immune markers were analyzed in conjunction with demographic, lifestyle, and medical history metadata. This comprehensive approach allowed for the identification of specific links between microbial and metabolic signatures and overall wellness, providing a contemporary baseline to enable the development of personalized prevention and treatment strategies to help safeguard oral and systemic public health.

  • Open Access

    Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels

    by Peter Suenaert, Anneleen Segers, Leen Rymenans, Hélène Devroye, Janne Marie Moll, Patrice D. Cani, Willem M. de Vos

    Pasteurized Akkermansia muciniphila MucT was found to improve barrier function in preclinical models and a proof-of-concept study in obese and prediabetic adults. Here, we describe the results of a double-blind placebo-controlled multicenter (Ireland and Germany) trial in 142 adults with metabolic syndrome, with or without prediabetes. The primary endpoint of whole-body insulin sensitivity (Matsuda index) did not differ after 4-months of daily administration of capsules containing 30 billion cells of pasteurized A. muciniphila MucT compared to placebo in the intention-to-treat subjects. Subsequent exploratory analyses showed that 3-months intake of pasteurized A. muciniphila MucT already improved HOMA-based hepatic insulin sensitivity in prediabetic (12%; p = 0.05) and 63-y-or-older-age subgroups (p = 0.05) while increasing post-OGTT excursion of the insulinotropic hormone glucagon-like peptide 1 (GLP-1) over placebo (p < 0.01). Further analysis of the gut microbiota by deep metagenomic analysis showed minor effects of the intervention but revealed that the baseline microbial composition differed from that in matched healthy adults. We found that participants with low baseline Akkermansia gene counts experienced significant health improvements and GLP-1 excursion after 3-months of treatment with pasteurized A. muciniphila MucT over the placebo. These benefits included improved insulin sensitivity (as shown by Matsuda and HOMA-S indices) and GLP-1 excursion (post-OGTT) (p < 0.05), reductions in body weight (p = 0.06) and decreased trunk fat (p < 0.05). In conclusion, daily supplementation with pasteurized A. muciniphila MucT has the potential to improve health markers in overweight or obese normo- or dysglycemic adults with the most significant improvements in subjects with low baseline intestinal Akkermansia levels, who are apparently truly in need of this intervention. Clinical trial registration no.: NCT05114018 clinicaltrials.gov.


  • Open Access

    The HUNT study identifies host genetic factors reproducibly associated with human gut microbiota composition

    by Marta Riise Moksnes, Eivind Coward, Maria Nethander, Koen Dekkers, Louise Grahnemo, Anna E. Törnqvist, Lei Li, Per Lundmark, Kamalita Pertiwi, Gabriel Baldanzi, et al.

    The gut microbiota is associated with human health and disease. Here we conducted a genome-wide association study of host genetic factors influencing gut microbiota composition in 12,652 individuals from the Trøndelag Health Study (HUNT), with replication in Nordic cohorts ( n = 16,017–21,976). We identified 12 reproducible SNP–species associations across six genomic loci, including known ( LCT , ABO ) and novel ( HLA-DQB1 , MUC12 , SLC37A2 , FUT2 ) regions. Additionally, we detected genetic signals associated with gut microbiota functional modules at three loci ( LCT , ABO , FUT2 ). Follow-up analyses suggest that these host–microbiota associations are linked to the pathogenesis of celiac disease and hemorrhoidal disease. Mendelian randomization analyses provided evidence supporting a causal effect of body mass index on gut microbiota composition. These findings highlight the interplay between host genetics and gut microbiota for human health and disease.


  • Top Cited Papers

    Early-life colonization by aromatic-lactate-producing bifidobacteria lowers the risk of allergic sensitization

    by Pernille Neve Myers, Rasmus Kaae Dehli, Axel Mie, Janne Marie Moll, Henrik Munch Roager, Carsten Eriksen, Martin Frederik Laursen, Ellen Magdalena Staudinger, Ioanna Chatzigiannidou, Pi Lærke Johansen, et al.

    Early-life microbial exposures shape immune development and allergy risk. Food allergen sensitization, reflected by the presence of food allergen-specific immunoglobulin E (IgE), is an early indication of impaired immune tolerance. Here we show that early-life transmission of aromatic lactate-producing bifidobacteria strains in 147 children followed from birth to 5 years of age, facilitated by vaginal delivery, exposure to older siblings and exclusive breastfeeding for the first 2 months, led to increased levels of aromatic lactates in the infant gut. This microbiota–metabolite signature was inversely associated with the development of food allergen-specific IgE until 5 years and atopic dermatitis at 2 years. The observed effect was mediated by 4-hydroxy-phenyllactate, which inhibited IgE, but not IgG, production in ex vivo human immune cell cultures. Together, these findings define an early-life microbiota–metabolite–immune axis linking microbial transmission and feeding practices with reduced allergic sensitization.


  • Open Access

    A young child formula with Limosilactobacillus reuteri and GOS modulates gut microbiome and enhances bone and muscle development: a randomized trial

    by Nicolas Bonnet, Maria Rosario Capeding, Léa Siegwald, Marc Garcia-Garcera, Thibaut Desgeorges, Hanne L. P. Tytgat, Laura-Florina Krattinger, Jowena Lebumfacil, Loudhie Cyd Phee, Janne Marie Moll, et al.

    In this randomized, double-blind controlled trial, 182 Filipino children aged 2-3 years received either an experimental young child formula (EYCF) containing a combination of Limosilactobacillus reuteri DSM 17938 and galacto-oligosaccharides (GOS; n = 91) or a minimally fortified milk (CM; n = 91) for 6 months. Primary outcome was tibia speed of sound and secondary outcomes were muscle strength, blood vitamin D levels, bone turnover markers, gut microbiota, fecal calcium fatty acid soaps and gastro-intestinal tolerance. Compared to CM, those in the EYCF group showed increased tibia speed of sound after 3 and 6 months. The intervention remodeled the stool microbiome composition, assessed by shotgun metagenomics, with enrichment of L. reuteri and higher bifidobacteria presence in the EYCF group. Increased L. reuteri abundance after 6 months of EYCF consumption associates with higher bone quality and muscle strength. Stool metabolomics show 45 metabolites modulated by EYCF consumption and associated to microbiome compositional changes, leading to enrichment of tryptophane and indole metabolism. In summary, consumption of EYCF containing a L. reuteri + GOS synbiotic improves musculoskeletal development in toddlers via modulation of microbiota composition and function. These results provide insights on gut-musculoskeletal crosstalk during early life. Clinicaltrial.gov NCT04799028.


  • Open Access

    Temporal dynamics and microbial interactions shaping the gut resistome in early infancy

    by Ioanna Chatzigiannidou, Pi L. Johansen, Rasmus K. Dehli, Janne Marie Moll, Carsten Eriksen, Pernille N. Myers, Henrik M. Roager, Lili Yang, Jakob Stokholm, Søren J. Sørensen, et al.

    Despite the critical role of the gut resistome in spreading of antimicrobial resistance (AMR), strategies to reduce the abundance of antibiotic resistance genes (ARGs) during microbiota development in infancy remain underexplored. Using longitudinal quantitative metagenomic data, we here show that ARGs are present in the gut microbiota from the first week of life, with a peak in absolute ARG abundance and richness at 6 months. Delivery mode significantly affects early ARG dynamics, and vaginally delivered infants exhibit higher ARG abundance due to maternal transmission of Escherichia coli strains harbouring extensive resistance repertoires. The abundance of E. coli and other ARG-rich taxa inversely correlates with aromatic lactic acid-producing bifidobacteria, and aromatic lactic acids strongly inhibit the in vitro growth of E. coli and other opportunistic ARG-rich taxa. Our results highlight temporal and critical microbial interactions shaping the gut resistome in early infancy, pointing to potential interventions to curb AMR during this vulnerable developmental window by promoting colonization of aromatic lactic acid-producing bifidobacteria.


  • Open Access

    Author Correction: Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial

    by Mary Ni Lochlainn, Ruth C. E. Bowyer, Janne Marie Moll, María Paz García, Samuel Wadge, Andrei-Florin Baleanu, Ayrun Nessa, Alyce Sheedy, Gulsah Akdag, Deborah Hart, et al.

  • Top Cited Papers
    Open Access

    Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial

    by Mary Ni Lochlainn, Ruth C. E. Bowyer, Janne Marie Moll, María Paz García, Samuel Wadge, Andrei-Florin Baleanu, Ayrun Nessa, Alyce Sheedy, Gulsah Akdag, Deborah Hart, et al.

    Studies suggest that inducing gut microbiota changes may alter both muscle physiology and cognitive behaviour. Gut microbiota may play a role in both anabolic resistance of older muscle, and cognition. In this placebo controlled double blinded randomised controlled trial of 36 twin pairs (72 individuals), aged ≥60, each twin pair are block randomised to receive either placebo or prebiotic daily for 12 weeks. Resistance exercise and branched chain amino acid (BCAA) supplementation is prescribed to all participants. Outcomes are physical function and cognition. The trial is carried out remotely using video visits, online questionnaires and cognitive testing, and posting of equipment and biological samples. The prebiotic supplement is well tolerated and results in a changed gut microbiome [e.g., increased relative Bifidobacterium abundance]. There is no significant difference between prebiotic and placebo for the primary outcome of chair rise time (β = 0.579; 95% CI −1.080-2.239 p = 0.494). The prebiotic improves cognition (factor score versus placebo (β = −0.482; 95% CI,−0.813, −0.141; p = 0.014)). Our results demonstrate that cheap and readily available gut microbiome interventions may improve cognition in our ageing population. We illustrate the feasibility of remotely delivered trials for older people, which could reduce under-representation of older people in clinical trials. ClinicalTrials.gov registration: NCT04309292.


  • Specific gut pathobionts escape antibody coating and are enriched during flares in patients with severe Crohn’s disease

    by Carsten Eriksen, Niels Banhos Danneskiold-Samsøe, Janne Marie Moll, Pernille Neve Myers, Pi W Bondegaard, Simone Vejrum, Tine Brodka Hansen, Lisbeth Buus Rosholm, Philipp Rausch, Kristine Højgaard Allin, et al.

    Objective: Patients with Crohn’s disease (CD) exhibit great heterogeneity in disease presentation and treatment responses, where distinct gut bacteria and immune interactions may play part in the yet unresolved disease aetiology. Given the role of antibodies in the barrier defence against microbes, we hypothesised that gut bacterial antibody-coating patterns may influence underlying disease-mediated processes.Design: Absolute and relative single and multicoating of gut bacteria with IgA, IgG1, IgG2, IgG3 and IgG4 in patients with CD and healthy controls were characterised and compared with disease activity. IgG2-coated and non-coated taxa from patients with severe CD were identified, profiled for pathogenic characteristics and monitored for enrichment during active disease across cohorts.Results: Patients with severe CD exhibited higher gut bacterial IgG2-coating. Supervised clustering identified 25 bacteria to be enriched in CD patients with high IgG2-coating. Sorting, sequencing andin silico-based assessments of the virulent potential of IgG2-coated and bulk stool bacteria were performed to evaluate the nature and pathogenicity of IgG2-coated and non-coated bacteria. The analyses demonstrated IgG2-coating of both known pathogenic and non-pathogenic bacteria that co-occurred with two non-coated pathobionts,CampylobacterandMannheimia. The two non-coated pathobionts exhibited low prevalence, rarely coincided and were strongly enriched during disease flares in patients with CD across independent and geographically distant cohorts.Conclusion: Distinct gut bacterial IgG2-coating was demonstrated in patients with severe CD and during disease flares. Co-occurrence of non-coated pathobionts with IgG2-coated bacteria points to an uncontrolled inflammatory condition in severe CD mediated via escape from antibody coating by two gut pathobionts.